Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) traded up 1.9% during trading on Wednesday . The company traded as high as $4.36 and last traded at $4.36, with a volume of 56,534 shares changing hands. The stock had previously closed at $4.28.

A number of analysts recently commented on the company. Zacks Investment Research downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. FBR & Co reissued a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research report on Sunday, May 22nd. Maxim Group set a $6.00 target price on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 18th. Finally, Rodman & Renshaw reissued a “buy” rating and issued a $17.00 target price on shares of Abeona Therapeutics in a research report on Wednesday, May 18th.

The stock’s market capitalization is $144.91 million. The stock has a 50 day moving average price of $3.17 and a 200-day moving average price of $2.80.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.06. On average, analysts predict that Abeona Therapeutics Inc. will post ($0.71) EPS for the current fiscal year.

An institutional investor recently raised its position in Abeona Therapeutics stock. Royce & Associates LLC increased its stake in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned approximately 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent filing with the SEC.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.